monocarboxypeptidas
gener
angiotensin
angiotensin
ii
attempt
target
kidney
renin
angiotensin
system
use
nativ
treat
kidney
diseas
hamper
larg
molecular
size
kda
preclud
glomerular
filtrat
subsequ
tubular
uptak
show
urin
kidney
lysat
capabl
digest
nativ
shorter
protein
kda
demonstr
enzymat
activ
truncat
nativ
design
cterminu
gener
two
short
recombin
r
variant
two
truncat
molecular
size
kda
expect
amino
acid
sequenc
shown
western
blot
enzym
activ
measur
use
specif
substrat
higher
nativ
aa
infus
mice
genet
defici
singl
iv
inject
result
detect
activ
urin
wherea
infus
nativ
moreov
activ
recov
harvest
kidney
mice
infus
control
creatinineh
proteinhr
respect
addit
kidney
mice
infus
studi
ex
vivo
form
ang
exogen
ang
ii
infus
vehicl
auc
vs
ngml
respect
p
demonstr
function
effect
increas
kidney
activ
infus
short
variant
conclud
novel
short
recombin
variant
undergo
glomerular
filtrat
associ
kidney
uptak
enzymat
activ
protein
enhanc
format
ang
ang
ii
small
variant
may
offer
potenti
use
approach
target
kidney
ra
overact
combat
kidney
injuri
angiotensin
convert
monocarboxypeptidas
degrad
sever
substrat
ang
ii
relev
extens
biolog
effect
peptid
attend
format
ang
action
gener
opposit
ang
ii
protein
fulllength
form
aminoacid
aa
typei
transmembran
protein
kda
contain
extracellular
domain
aa
transmembran
region
aa
intracellular
tail
extracellular
part
aa
refer
nativ
contain
catalyt
domain
fulli
catalyt
activ
previou
studi
administr
nativ
aa
result
mark
increas
circul
activ
neither
kidney
urinari
activ
increas
lack
increas
urinari
activ
inject
nativ
attribut
lack
glomerular
filtrat
nativ
consist
larg
molecular
size
kda
markedli
increas
circulatori
level
activ
nativ
administr
capabl
effect
lower
blood
pressur
model
ang
iiinduc
hypertens
renin
overexpress
circul
use
suitabl
treatment
form
kidney
diseas
instanc
diabet
model
local
kidney
system
ra
overact
longterm
augment
circul
activ
suffici
alter
glomerular
patholog
gfr
albuminuria
observ
provid
rational
develop
shorter
form
molecular
size
render
filtrabl
kidney
therefor
potenti
use
therapeut
amplifi
activ
form
kidney
diseas
overact
local
ra
kidney
tissu
enzym
low
level
activ
plasma
urin
enzymat
activ
substanti
two
distinct
band
report
mice
human
urin
one
band
kd
correspond
expect
molecular
weight
nativ
kd
kd
band
like
result
shed
kidney
apic
tubular
membran
protein
abundantli
express
band
detect
mous
urin
lower
size
kd
origin
whether
activ
remain
unclear
base
observ
hypothes
variant
shorter
molecular
size
could
gener
still
retain
enzymat
activ
accordingli
sought
develop
short
variant
small
enough
could
filter
subsequ
reabsorb
kidney
tubul
kidney
uptak
small
variant
turn
would
foster
ang
format
ang
ii
therebi
provid
novel
direct
approach
target
kidney
ra
overact
form
kidney
diseas
includ
acut
kidney
injuri
kidney
cortex
total
protein
fraction
extract
previous
describ
urin
contain
mg
total
protein
kidney
cortex
lysat
contain
mg
total
protein
mice
genet
background
mix
mm
hepe
ph
nacl
mm
triton
zncl
endconcentr
incub
nativ
mous
nm
c
constantli
shake
rpm
h
specifi
time
point
incub
aliquot
taken
mix
equal
volum
pb
buffer
contain
edtafre
inhibitor
cocktail
roch
basel
switzerland
immedi
frozen
aliquot
use
measur
activ
use
mcaapkdnp
substrat
detect
protein
western
blot
western
blot
protein
separ
sdspage
transfer
nitrocellulos
membran
membran
block
nonfat
dri
milk
wtvol
solubil
trisbuff
salin
solut
contain
tween
nitrocellulos
membran
incub
primari
antibodi
r
system
minneapoli
mn
usa
abcam
cambridg
usa
horseradish
peroxidaseconjug
secondari
antibodi
santa
cruz
biotechnolog
specif
antibodi
confirm
absenc
band
western
blot
use
sampl
previous
report
band
visual
use
chemiluminesc
system
super
signal
pico
pierc
rockford
il
usa
gener
short
fragment
exhibit
activ
seri
dna
construct
vari
length
gener
truncat
c
terminu
supplementari
materi
figur
cdna
short
gener
pcr
amplif
use
templat
cdna
intact
solubl
mous
code
amino
acid
gradual
shorten
use
specif
primer
determin
length
shorter
cdna
amplifi
compat
express
vector
restrict
site
pcdna
invitrogen
carlsbad
ca
usa
absenc
mutat
amplifi
cdna
verifi
sequenc
plasmid
insert
cdna
short
variant
express
transient
transfect
cell
activ
measur
condit
cultur
medium
use
fluorometr
substrat
mcaapkdnp
supplementari
materi
figur
nativ
contain
full
extracellular
domain
aa
use
posit
control
neg
control
condit
media
mocktransfect
cell
use
addit
western
blot
use
polyclon
antibodi
rais
entir
extracellular
domain
r
system
use
detect
transgen
confirm
molecular
size
overexpress
small
variant
two
short
enzymat
activ
variant
select
larg
scale
product
purif
stabli
transfect
hek
cell
singl
clone
select
expand
ml
flask
condit
serumfre
medium
clone
stabli
transfect
hek
cell
overexpress
two
short
variant
subject
anion
exchang
qcolumn
akta
chromatographi
system
mm
trishcl
ph
elut
appli
increas
concentr
nacl
elut
fraction
screen
activ
use
mcaapkdnp
substrat
fraction
contain
activ
appli
sdspage
transfer
pvdf
membran
stain
brilliant
blue
assess
protein
puriti
supplementari
materi
figur
show
exampl
compar
enzymat
activ
highli
purifi
enzymat
activ
short
protein
test
abil
cleav
main
natur
substrat
ang
ii
form
ang
measur
assay
measur
releas
ctermin
amino
acid
phenylalanin
form
byproduct
cleavag
ang
ii
ang
rel
enzymat
potenc
short
fragment
determin
comparison
equival
molar
amount
intact
aa
long
use
benchmark
assess
activ
level
michaelismenten
model
use
deriv
paramet
catalyt
kinet
km
kcat
studi
effect
small
variant
ang
iiinduc
hypertens
inject
week
old
male
mice
ip
either
vehicl
pb
mous
mous
bodi
weight
h
mice
anesthet
ip
inject
ketamin
mgkg
bodi
weight
mice
place
temperaturecontrol
platform
min
immedi
anesthesia
induc
systol
bp
monitor
noninvas
everi
period
min
previous
describ
five
minut
baselin
sbp
record
acut
hypertens
anesthet
mice
induc
ip
bolu
inject
ang
ii
mgkg
bodi
weight
sbp
monitor
consecut
mode
interv
throughout
remain
min
time
period
recoveri
urinari
recombin
infus
mice
effect
block
tubular
reabsorpt
llysin
immedi
mice
void
urin
baselin
urin
collect
purifi
mous
recombin
protein
administ
singl
iv
bolu
inject
dose
bodi
weight
order
determin
impact
protein
reabsorpt
proxim
tubul
lysin
blocker
proxim
tubular
reabsorpt
also
administ
mgg
bodi
weight
singl
ip
inject
timelin
experi
follow
mice
weight
follow
collect
baselin
urin
level
within
min
void
urin
mice
administ
protein
singl
iv
inject
mlmous
bw
immedi
iv
inject
collect
urin
mice
place
h
urin
collect
cage
access
water
food
afterward
llysin
inject
ip
urin
collect
within
h
subsequ
ip
inject
tubular
reabsorpt
blocker
llysin
mgg
bodi
weight
pharmacokinet
profil
mous
assess
balbc
mice
compar
nativ
mous
mice
receiv
singl
iv
ip
inject
purifi
small
variant
dose
bodi
weight
blood
sampl
collect
tail
bleed
either
number
indic
time
point
inject
blood
sampl
collect
heparin
capillari
left
undisturb
ice
plasma
isol
centrifug
g
min
c
mcaapk
dnp
substrat
bachem
bubendorf
bl
switzerland
pa
use
measur
enzym
activ
plasma
halflif
area
plasma
activ
time
curv
mean
resid
time
speci
calcul
use
prism
softwar
graphpad
la
jolla
ca
usa
comparison
two
independ
group
twotail
ttest
use
data
normal
distribut
normal
distribut
assess
use
shapirowilk
test
normal
distribut
data
mannwhitney
test
use
comparison
two
independ
group
oneway
anova
employ
follow
tukey
multipl
comparison
test
comparison
ang
format
sbp
time
anova
use
pvalu
consid
statist
signific
result
present
mean
se
mous
urin
two
band
present
fresh
kidney
lysat
howev
kd
band
found
consist
molecular
size
nativ
mous
unclear
whether
lower
kd
band
product
nativ
degrad
distinct
protein
therefor
decid
examin
possibl
kd
band
could
proteolyt
digest
product
kd
band
studi
hypothesi
proteolysi
urin
kidney
mice
spike
nativ
gener
overexpress
purifi
nativ
recombin
mous
mr
molecular
size
kd
amino
acid
long
contain
polyhi
tag
cterminu
sampl
knockout
mice
use
elimin
interfer
aris
endogen
spike
nativ
kd
urin
kidney
incub
h
c
enabl
proteolysi
nativ
urinari
kidney
proteas
respect
small
sampl
reaction
mixtur
taken
analysi
differ
time
point
within
h
incub
time
kidney
lysat
extend
incub
result
format
kd
band
also
kd
immunoreact
band
signific
activ
figur
spike
nativ
urin
ko
result
similarli
appear
kd
band
gradual
fade
nativ
kd
kidney
lysat
h
incub
band
activ
seen
urin
confirm
consist
time
cours
degrad
studi
describ
three
differ
urin
three
differ
kidney
lysat
incub
nativ
kd
c
six
hour
timepoint
chosen
robust
band
found
urin
kidney
lysat
consist
data
shown
figur
kd
nativ
protein
convert
urin
kidney
lysat
band
appar
molecular
size
kd
figur
kd
immunoreact
band
appear
exhibit
high
specif
enzym
activ
similar
origin
kd
band
use
spike
figur
suggest
kidney
urin
contain
proteas
capabl
digest
nativ
enzymat
activ
truncat
kd
nativ
use
spike
contain
ctermin
tag
reprob
membran
antihi
antibodi
reveal
band
size
origin
nativ
kda
fail
detect
lower
band
kd
figur
ntermin
cleavag
nativ
disprov
find
clearli
show
proteolysi
mous
urin
kidney
take
place
ctermin
site
figur
reprob
use
antihi
antibodi
western
blot
imag
show
disappear
kd
band
appear
smaller
kd
immunoreact
band
urin
kidney
lysat
mice
suggest
proteolysi
nativ
ctermin
end
urin
kidney
lysat
three
independ
degrad
experi
base
find
gener
ctermin
truncat
recombin
mous
protein
see
method
supplementari
materi
figur
molecular
size
sequenc
three
short
variant
provid
supplement
supplementari
figur
enzym
activ
variant
evalu
condit
medium
compar
overexpress
nativ
use
benchmark
enzym
activ
condit
cultur
media
hek
cell
transient
transfect
construct
gener
truncat
c
terminu
aa
aa
least
high
media
collect
cell
overexpress
nativ
judg
kinet
slope
figur
contrast
transfect
shorter
fragment
aa
show
enzym
activ
figur
two
enzymat
activ
short
variant
appear
singl
band
appar
molecular
weight
kda
expect
amino
acid
sequenc
deduct
use
expasi
informat
tool
figur
figur
enzymat
inact
variant
appear
addit
expect
size
kd
oligomer
form
band
higher
molecular
weight
figur
suggest
minim
length
requir
ctermin
end
murin
enzymat
activ
contain
aa
clonal
cell
line
stabli
express
two
variant
establish
recombin
protein
purifi
cultur
medium
strong
anionexchang
chromatographi
shown
supplementari
figur
see
detail
method
purifi
nativ
use
control
compar
enzymat
activ
two
short
variant
catalyt
effici
two
short
variant
kcatkm
cleav
synthet
fluorogen
substrat
mcaapk
dnp
higher
compar
nativ
fact
fourfold
threefold
higher
compar
enzymat
activ
nativ
figur
use
ang
ii
natur
substrat
catalyt
effici
k
cat
k
found
differ
nativ
two
shorter
protein
figur
n
experi
protein
pharmacokinet
profil
determin
mice
compar
use
mcaapk
dnp
assay
measur
activ
serum
collect
time
seri
follow
singl
iv
inject
form
bw
see
method
rel
short
distribut
phase
blood
follow
longer
elimin
phase
figur
tabl
distribut
phase
halflif
min
differ
min
nativ
min
three
time
longer
elimin
phase
halflif
p
h
p
respect
compar
h
tabl
calcul
area
curv
reflect
overal
vivo
pharmacolog
efficaci
also
higher
around
time
two
small
variant
p
compar
nativ
tabl
addit
maximum
serum
activ
two
short
protein
much
higher
nativ
figur
mean
resid
time
also
higher
nativ
p
variant
differ
reach
statist
signific
tabl
follow
ip
infus
method
deliveri
use
previou
studi
expect
delay
achiev
peak
blood
activ
level
short
figur
tabl
compar
level
obtain
use
iv
administr
tabl
similar
iv
inject
ip
administr
maximum
serum
activ
calcul
auc
nativ
lower
two
shorter
variant
figur
elimin
phase
halflif
mean
resid
time
howev
lower
compar
two
shorter
protein
tabl
tabl
mean
se
pharmacokinet
paramet
nativ
truncat
blood
circul
mice
ip
administr
overal
small
variant
exhibit
higher
serum
activ
nativ
iv
ip
administr
variant
longest
circulatori
resid
time
iv
inject
tabl
effect
short
acut
hypertens
examin
model
angiotensin
iiinduc
hypertens
previous
describ
us
mice
pretreat
either
vehicl
pb
singl
ip
inject
h
receiv
bolu
inject
ang
ii
figur
blood
pressur
mice
monitor
continu
light
anesthesia
time
seri
interv
start
five
minut
ang
ii
inject
see
method
inject
ang
ii
result
rapid
increas
systol
blood
pressur
peak
mm
hg
baselin
mm
hg
control
group
receiv
pb
preinject
vehicl
figur
b
respect
increas
sbp
effici
mitig
similar
extent
treatment
group
figur
b
sinc
normal
present
urin
better
assess
whether
increas
urinari
activ
administr
short
variant
inject
defici
mice
urinari
activ
measur
use
mcaapkdnp
fluorogen
substrat
expect
enzymat
activ
detect
baselin
urin
collect
infus
mice
creath
n
iv
infus
result
increas
activ
mice
n
extent
respect
urin
collect
h
inject
western
blot
moreov
show
band
iv
infus
figur
examin
whether
glomerular
filtrat
tubular
uptak
filter
take
place
mice
infus
either
nativ
neg
control
subsequ
llysin
blocker
proxim
tubular
protein
reabsorpt
inject
ip
figur
inject
nativ
inject
urinari
activ
detect
consist
lack
glomerular
filtrat
larg
nativ
tubular
reabsorpt
blocker
llysin
moreov
result
appreci
gain
urinari
activ
figur
contrast
small
recombin
variant
infus
mice
result
clear
gain
urinari
activ
block
llysin
increas
urinari
activ
demonstr
two
truncat
filter
reabsorb
tubul
figur
aggreg
data
show
must
undergo
glomerular
filtrat
subsequ
proxim
tubular
reabsorpt
examin
whether
kidney
mice
infus
gain
substanti
activ
truncat
inject
kidney
harvest
infus
figur
isol
kidney
cortic
mice
activ
detect
either
pbsor
mice
contrast
kidney
cortex
activ
clearli
detect
proth
significantli
higher
pb
proth
p
group
proth
p
figur
ex
vivo
experi
kidney
mice
spike
ang
ii
also
exhibit
significantli
higher
ang
format
kidney
pbsmice
p
nativ
mice
p
anova
figur
show
kidney
uptak
translat
increas
kidney
activ
capabl
ang
ii
ang
convers
figur
glomerular
filtrat
tubular
uptak
blue
n
green
n
compar
nativ
red
n
mice
immedi
void
baselin
urin
collect
mice
inject
iv
bw
urin
collect
within
first
h
llysin
inject
ip
two
hour
urin
collect
within
next
h
recoveri
urin
normal
creatinin
excret
depict
repeat
measur
oneway
anova
use
comparison
within
experiment
group
follow
posthoc
analysi
denot
p
p
studi
describ
design
test
novel
recombin
mous
protein
molecular
size
kd
much
shorter
nativ
two
short
variant
activ
system
molecular
size
short
enough
render
filter
kidney
glomerular
filtrat
barrier
short
variant
moreov
reabsorb
kidney
tubul
thu
capabl
amplifi
kidney
activ
foster
format
ang
ang
ii
featur
make
attract
combat
vast
array
kidney
diseas
ra
overact
acut
kidney
injuri
other
previous
identifi
two
main
band
mous
urin
one
band
kd
correspond
molecular
weight
nativ
like
product
shed
like
mediat
metalloproteas
kidney
apic
tubular
membran
abundantli
express
observ
prompt
us
investig
shorter
form
kd
enzymat
activ
design
shorter
one
test
potenti
activ
vitro
vivo
demonstr
natur
kda
degrad
urin
kidney
shorter
fragment
retain
enzym
activ
kd
band
result
proteolyt
cleavag
kda
determin
demonstr
recombinantli
gener
nativ
recombin
kda
digest
kidney
urin
proteas
shorter
band
similar
size
kda
fragment
natur
observ
urin
figur
experi
also
abl
ascertain
ctermin
end
site
remov
nativ
without
loss
enzym
activ
figur
find
consist
crystallograph
homolog
studi
human
indic
ctermin
end
fairli
larg
structur
portion
nonenzymat
function
next
proceed
demonstr
longer
exposur
kda
nativ
proteas
kidney
result
format
even
kda
band
show
still
high
enzymat
activ
figur
contrast
urin
extend
incub
nativ
ultim
led
disappear
kda
band
loss
activ
suggest
unlik
kidney
truncat
prevail
extend
period
time
urin
equip
repertoir
proteas
inactiv
digest
small
inact
fragment
investig
howev
specif
proteas
respons
cleavag
cleavag
site
studi
done
futur
base
find
ex
vivo
proteolysi
nativ
gener
short
variant
vari
length
gradual
truncat
ctermin
end
shortest
activ
variant
aa
long
kda
longer
variant
exhibit
enzymat
activ
well
contrast
short
variant
aa
enzymat
inact
figur
preliminari
conclus
minimum
length
requir
activ
somewher
aa
two
activ
short
protein
purifi
vivo
effect
compar
nativ
halfliv
inject
recombin
protein
evalu
figur
tabl
compar
nativ
blood
halflif
h
iv
administr
substanti
extend
halflif
around
h
addit
area
curv
short
protein
higher
nativ
iv
inject
tabl
higher
ip
administr
tabl
also
noteworthi
dose
peak
plasma
activ
infus
short
variant
substanti
higher
nativ
figur
suggest
better
pharmacolog
profil
compar
nativ
form
note
howev
pharmacokinet
profil
base
activ
assess
artifici
substrat
catalyt
effici
toward
artifici
substrat
likewis
much
higher
nativ
figur
contrast
catalyt
effici
assess
use
natur
substrat
ang
ii
signific
differ
short
variant
nativ
figur
test
system
effect
short
variant
vivo
use
establish
protocol
acut
ang
iiinduc
hypertens
use
protocol
previous
demonstr
lower
plasma
ang
ii
use
nativ
effect
mitig
increas
blood
pressur
caus
ang
ii
administr
similar
nativ
small
variant
blunt
peak
increas
blood
pressur
ang
ii
infus
normal
faster
within
five
minut
less
show
small
variant
effici
degrad
excess
system
circul
ang
ii
therebi
enhanc
blood
pressur
recoveri
demonstr
system
effect
blood
pressur
studi
whether
small
variant
ad
effect
system
action
local
urinari
kidney
level
normal
present
urin
better
assess
whether
increas
urinari
activ
administr
short
variant
mice
use
contrast
nativ
inject
small
recombin
variant
result
gain
urinari
activ
llysin
tubular
reabsorpt
blocker
increas
urinari
activ
suggest
two
short
variant
filter
reabsorb
tubul
short
protein
variant
taken
kidney
inde
enzymat
activ
shown
presenc
activ
kidney
defici
mice
inject
addit
kidney
cortex
lysat
mice
abl
form
significantli
ang
ang
ii
kidney
lysat
pbsor
nativ
mice
aggreg
data
show
mous
short
variant
activ
suffici
small
filter
kidney
moreov
capabl
increas
kidney
activ
extent
ang
format
ang
ii
increas
figur
limit
studi
acknowledg
studi
perform
blind
fashion
potenti
bia
measur
activ
urin
kidney
level
prevent
stratifi
random
treat
anim
regard
knockout
allow
us
demonstr
urin
kidney
activ
inject
short
variant
rel
easili
show
case
infus
nativ
use
nativ
control
enhanc
result
obtain
novel
short
variant
strength
design
even
though
pharmacokinet
data
show
clear
superior
short
variant
compar
nativ
caution
emphas
effect
may
depend
artifici
substrat
use
measur
activ
know
kidney
activ
increas
administr
short
variant
natur
question
clinic
condit
kidney
amplif
could
use
specul
diseas
condit
local
kidney
ra
overact
would
natur
target
sever
studi
use
diabet
model
show
activ
ra
local
within
kidney
glucos
includ
increas
ang
ii
product
addit
evid
come
find
increas
ra
compon
kidney
urin
rodent
model
diabet
kidney
diseas
dkd
patient
dkd
nondiabet
ckd
need
new
approach
counteract
ra
overact
expand
improv
exist
one
base
blockad
ang
ii
format
action
chosen
therapeut
target
enzym
cleav
ang
ii
form
ang
highest
effici
sever
potenti
indic
small
variant
treatment
kidney
diseas
particular
think
acut
kidney
injuri
aki
may
benefit
administr
small
variant
way
calm
kidney
ra
overact
clinic
syndrom
pathogenesi
aki
complex
often
involv
hemodynam
nonhemodynam
mechan
alter
ra
shown
contribut
develop
aki
associ
advers
outcom
experiment
clinic
studi
sever
compon
kidney
ra
urin
angiotensinogen
ang
ii
main
activ
peptid
increas
experiment
aki
caus
ischemiareperfus
aki
ace
inhibitor
acei
angiotensin
receptor
antagonist
arb
may
attenu
renal
inflamm
injuri
improv
renal
function
ischemiareperfus
model
aki
intraren
ang
ii
reportedli
elev
aki
may
worsen
kidney
tissu
injuri
independ
hemodynam
effect
help
maintain
renal
circul
base
consider
current
studi
effect
mous
model
aki
summari
develop
short
variant
improv
pharmacokinet
properti
compar
nativ
short
protein
variant
unlik
intact
protein
undergo
glomerular
filtrat
tubular
uptak
kidney
uptak
enzymat
activ
short
variant
enhanc
local
format
ang
ang
ii
administr
activ
small
variant
offer
therapeut
potenti
prevent
treatment
acut
kidney
injuri
directli
reduc
kidney
ra
overact
retain
system
effect
activ
amplif
supplementari
materi
follow
avail
onlin
http
figur
gener
test
recombin
protein
truncat
figur
purif
short
mous
figur
amino
acid
sequenc
molecular
weight
mous
truncat
fund
work
mainli
support
nation
institut
diabet
digest
kidney
diseas
grant
discretionari
fund
daniel
batll
northwestern
univers
